1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Heart Failure: Global Drug Forecast and Market Analysis to 2028

Heart Failure: Global Drug Forecast and Market Analysis to 2028

  • December 2019
  • 190 pages
  • ID: 5844159
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Heart Failure: Global Drug Forecast and Market Analysis to 2028

Summary
Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply.This can be due to structural or functional cardiac abnormalities which can be caused by unexpected injury such as myocardial infarction, or an underlying pathogenesis such as hypertension (Krum and Abraham, 2009).

The heart then begins to employ compensatory mechanisms that soon become maladaptive - Frank-Starling mechanism, neurohormonal activation and ventricular remodeling.All of which help to relieve stress initially but long term, cause strain on the cardiac muscle and inevitably progression of HF.

Heart failure can be either acute or chronic, depending on the manifestation time frame. Heart failure is grouped into subtypes which are defined by measure of ejection fraction - the heart’s ability to eject blood.

HF is a global healthcare concern and affected patients suffer from poor quality of life and poor prognosis.Risk factors for HF include; diabetes, hypertension and obesity, all of which are on the rise in the current population.

There is a large unmet need in HF for a treatment option that meets clinical end points in reduced mortality and hospitalization.

Key Highlights
- The main driver of the HF market expansion will be the approval and launch of the SGLT inhibitors for both HF-REF and HF-PEF.
- Another prominent contributor to sales growth will be the approval of the large number of pipeline therapies across the 8MM.
- The major global barrier for the HF market will be the annual cost of therapy for new pipeline drugs compared to the standard of care generics, alongside the unwillingness for prescribers to add new drugs to large therapy regimens.
- The key market opportunities lie in addressing unmet needs through the development of more efficacious drugs for HF patients for acute HF , HF-PEF and HF-mrEF.

Key Questions Answered
- SGLT inhibitors will enter the market and see a significant uptake in patient shares for the treatment of HF.However, there are high unmet needs within the indication.

What are the main unmet needs in this market? Will the drugs under development fulfill the unmet needs of the HF market?
- The current late-stage HF pipeline consists of chronic therapies such as Farxiga and Jardiance, post-acute therapies such as omecamtiv mecarbil and Zynquista, and acute therapies such as istaroxime.Will the late-stage drugs make a significant impact on the HF market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a significant increase in the HF population, in terms of diagnosed prevalence and there is an increase in the amount of patients treated for HF-REF, HF-PEF and HF-mrEF.

How will epidemiological changes impact the growth of the future market?

Scope
- Overview of HF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HFtherapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HF market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global HF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HF therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global HF therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Autoinjectors Market by Therapy, Type, Route of administration, End User - Global Forecast to 2025

  • $ 4950
  • December 2020
  • 177 pages

The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence ...

  • World
  • United States
  • Chronic Disease
  • Pharmaceutical
  • Industry analysis
  • Health Expenditure
  • Drug Approval

ref:plp2019

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on